CogENT Therapeutics™, LLC Announces FDA 510(k) Approval of XeroGel™ Nasal/Epistaxis Pack

HAYWARD, Ca., October 23, 2012 -- CogENT Therapeutics, LLC, an innovative ear, nose and throat medical device company, announced today the FDA 510(k) approval of its first commercial product, the XeroGel™ nasal/epistaxis pack, a novel product indicated for use in nasal/sinus surgery to minimize bleeding, separate tissues, prevent adhesion formation between mucosal surfaces, aid in the natural wound healing process, and treat epistaxis.

XeroGel provides a unique combination of inherent hemostatic properties, turgidity during wound healing, and thorough, consistent dissolution to enhance patient comfort during follow up exams. The product combines CogENT's proprietary polymer platform combining chitosan (a potent hemostatic biopolymer) with polyethylene glycol (a well- characterized synthetic polymer) to address the shortcomings and limitations of currently available splints, packs, and dressings used in ENT surgery.

"XeroGel's cohesive, crosslinked network is designed to help minimize post operative bleeding while acting as a turgid spacer to maintain tissue separation during the critical post operative healing window. Furthermore, XeroGel dissolves to a mucus-like consistency that is eliminated through natural outflow, significantly decreasing the need for aggressive, often painful debridement at follow up," commented Suresh Pai, CEO of CogENT Therapeutics.

About CogENT Therapeutics, LLC

CogENT Therapeutics, LLC (www.cogent-tx.com) is a privately held company pioneering innovative biomaterial and device solutions focused on improving the lives of patients suffering from ear, nose and throat (ENT) disorders. CogENT Therapeutics can be contacted at 650.450.4956 or infoandsales@cogent-tx.com.